In a single-arm, phase II HER2-negative locally advanced GC study, the R0 removal rate of Sintilimab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) was 93.1%. The gene discussed is ERBB2; the disease is gastric cancer.